CD40 and mesothelioma: These original immunotherapeutic strategies involved the administration to mesothelioma-bearing animals of systemic cytokines, such as recombinant interferon alpha (IFNα) (Bielefeldt-Ohmann et al., 1995) and also activating anti-CD40 antibodies (Stumbles et al., 2004; Khong et al., 2012).